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Aim: To study the influence of polyamine metabolism inhibitors on the growth, metastasis and ornithine decarboxylase (ODC) 
activity of Lewis lung carcinoma. Materials and Methods: Experiments were performed on female mice C57Bl/6 with Lewis lung 
carcinoma. Nω-hydroxy-nor-arginine (nor-NOHA) and α-difluoromethylornithine (DFMO) were used as arginase and ODC 
inhibitors, correspondently. Inhibition of tumor growth was calculated by comparison of tumor volume in the treated and control 
groups. The average number of metastases per animal in the group and the average volume of pulmonary metastases per animal 
in the group have been determined. Determination of ODC — the key enzyme of the polyamine synthesis — in the samples of ex-
perimental tumors was performed by method of Luqman S. Results: Administration of DFMO or it’s combination with nor-NOHA 
resulted in the decrease of tumor growth rate, number and volume of lung metastases and was accompanied with reduced ODC 
activity in tumor tissue. Сonclusion: Modifiers of polyamine metabolism may be considered as promising targeted cancer therapy.
Key Words: Lewis lung carcinoma, metastases, polyamine metabolism, ornithine decarboxylase, α-difluoromethylornithine, Nω-
hydroxy-nor-arginine.
Polyamines (PA) — putrescine, spermidine and 
spermine — natural polycations, which play a crucial 
role in many fundamental biological processes: DNA 
replication, transcription, translation, membrane protein 
function, protein folding and others [1–6]. The level 
of PA largely vary during physiological and pathological 
processes (embryogenesis, ageing [7–9], regenera-
tion, infections, malignant transformation [10, 11]).
The increased level of PA in tumor growth is used 
as a marker for monitoring in course of a disease 
and efficiency of therapy [12–14]. Inhibition the level 
of PA by blocking the activity of the key enzyme for pu-
trescine synthesis ornithine decarboxylase (ODC) — 
one of the most promising directions in the develop-
ment of new approaches to the cancer treatment. 
PA metabolism is regulated at different levels by a com-
plex system of enzymes, which are prima rily enzymes 
of PA synthesis and transformation. The modification 
of genes regulating PA metabolism by external factors, 
not studied enough. The aim of this work was to study 
the effect of inhibitors of PA metabolism on the growth 
and metastasis of experimental Lewis lung carcinoma 
in mice.
MATERIALS AND METHODS
Experiments were per formed on female 
C57Bl/6 mice 16.2–23 g. Tumor strain Lewis lung car-
cinoma was obtained from National Bank of Cell Lines 
and Transplanted Tumors of R.E. Kavetsky Institute 
of Experimental Pathology, Oncology and Radiobio-
logy, NAS of Ukraine (Kyiv, Ukraine). All experiments 
were conducted in accordance to international rules 
of work with laboratory animals [15]. Lewis lung car-
cinoma transplanted intramuscularly into the shin 
of the right rear leg 3•105 tumor cells in a volume 
of 0.2 ml of sterile isotonic sodium chloride solution. 
Animals were kept on a normal diet with free access 
to water. Each treatment group had 3–6 animals, con-
trol group — 4 mice.
Inhibitors applied: arginase inhibitor — Nω-
hydroxy-nor-arginine (nor-NOHA) (Cayman Chemical, 
USA), inhibitor of ODC — α-difluoromethylornithine — 
DFMO (Centre de Recherche Merrell International, 
16 rue d’Ankara, 67084 Strasbourg Cedex, France).
nor-NOHA prepared immediately before use and 
injected into the abdominal cavity of mice in a dose 
of 60 mg/kg (1.2 mg per mouse in 0.2 ml of isotonic so-
dium chloride solution) starting 7 days after tumor trans-
plantation. A comparative analysis was performed versus 
a group of non-treated tumor-bearing mice (control).
In each treatment group, 5 injections of an inhibitor 
were made. Control animals injected with 0.2 ml of ste-
rile isotonic sodium chloride solution. The volume 
of tumors registered throughout the experiment. 
The animals were decapitated 1 day after the last in-
jection of the inhibitors that is 14th day, and on the 26th 
day after tumor transplantation.
The kinetics of tumor growth evaluated by means 
of measuring tumor diameters. Inhibition of tumor 
growth was calculated by comparison of tumor vo lume 
in the treated and control groups. To assess the inten-
sity of the process of metastasis was used the following 
criteria: the average number of pulmonary metasta-
ses per animal in the group and the average volume 
of metastases per animal in the group. In these studies, 
the number and volume of lung metastases in un-
treated animals and in animals treated as described 
above for the tumor growth delay studies were scored 
on day 26 post-tumor implant. The number and volume 
of metastases were counted in the transmitted light 
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after removal of the lung, fixing it between the glass 
plates. Tumor volume was calculated by the formula: 
V = a2 · b · π/6, 
where a — short, b — longer diameter of tumor.
The metastas is inhibition index (MII) was calculated 
by the formula: 
MII = ((Ac − Ae)/Ac) · 100, 
where Ac — the number of metastases to the lung 
in mice of the control group and Ae — the frequency 
of metastases in a treated group.
Determination of the ODC activity in the samples 
of expe rimental tumors was performed by meth-
od S. Luqman [16, 17]. The method is based on the fact 
that the correspon ding enzyme converts L-ornithine 
hydrochloride (substrate) to the yellow colored pu-
trescine adduct soluble in pentanol, which measured 
by spectrophotometer.
The statistic processing of obtained results was 
conducted with the help of Student’s t-criterion. The 
data were reported as the M ± m.
RESULTS AND DISCUSSION
Arginine is a precursor for ornithine which may 
be then converted into putrescine — the first partici-
pant in metabolic transformations of PA [18]. It was 
found that DFMO — specific inhibitor of ODC — pre-
vents progression of cancer cells in model systems 
[19]. L-arginine is a nonessential amino acid that plays 
a central role in several biological systems includ-
ing the immune response. L-arginine is metabolized 
by arginase I and arginase II with farther creation of or-
nithine [20]. In our experiments, the effect of PA syn-
thesis inhibitors — DFMO and a competitive inhibitor 
of ornithine synthesis nor-NOHA — on the Lewis lung 
carcinoma growth has been performed. The results 
are presented in Fig. 1, Table 1.
As can be seen, there is a significant inhibition of tu-
mor growth begining of the eleventh day of the experi-
ment. During the experiment, both inhibitors studied 
demonstrate inhibi ting activity (within 28–43%).
In this regard, it was important to follow the changes 
in the dynamics of tumor growth that presented in Fig. 1.
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Fig. 1. Lewis lung carcinoma gro wth in mice under the influence 
of inhibitors of PA metabolism. *Significant difference (p < 0.05) 
with each experimental group (excluding the DFMO + nor-NOHA 
group at the 11th day, see Table 1)
Assessing the growth rate of the primary tumor 
node, it was found that  average  daily increase of tumor 
volume in the control group of animals within 9 days 
(11–20 days) was 497.2 ± 56.0 mm3. The use of both 
studied inhibitors and their combination led to a sig-
nificant reduction in the rate of growth, t he latter was 
about 300 mm3 d uring the same time period. Signifi-
cant difference in the impact on growth inhibition when 
using different inhibitors was not found (Fig. 2).
Table 1. Inhibition of growth of Lewis lung carcinoma in mice under influ-
ence of inhibitors of PA metabolism
Groups
Nu
m
be
r 
of
 a
ni
m
al
s  The volume of tumors, mm3 Inhibition, %
11th day 13th day 20th day 11
th 
day
13th 
day
20th 
day
Control 4 1067 ± 133 2123 ± 165 5542 ± 439 − − −
nor-NOHA 5 690 ± 129* 1194 ± 163* 3163 ± 662* 35.3 43.0 43.0
DFMO 4 633 ± 114* 1534 ± 232* 3305 ± 461* 40.7 28.0 40.0
D F M O + 
nor-NOHA 3 754 ± 138 1439 ± 149* 3504 ± 281* 0 32.0 37.0
Note: *p < 0.05 as compared to control.
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Fig. 2. T he rate of tumor growth of Lewis lung carcinoma in mice 
during 11–20 days compared to control
It is known that transplanted Lewis lung carcinoma 
refers to metastatic tumors, so anti-metastatic effect, 
as to this tumor strain, is an important indicator of antitu-
mor effect. The results of the next section of experiments 
devoted to examining the influence of inhibitors of PA me-
tabolism on the growth of lung metastases (Table 2).
Table 2. E ffect of inhibitors of PA metabolism on the number and volume 
of metastases of Lewis lung carcinoma in mice (26th day)
Groups
Number 
of ani-
mals
 The average number 
of metastases 
per 1 animal
 The average volume 
of metastases 
per 1 animal
n MІІ, % mm3 МІІ, %
Control 4 11.0 ± 2.2 − 160.1 ± 44.1 −
nor-NOHA 5 16.6 ± 3.2 0 138.8 ± 44.2 0
DFMO 4 12.0 ± 0.7 0 9.8 ± 2.3* 94
DFMO + nor-NOHA 3 11.0 ± 2.3 0 11.9 ± 5.3* 93
Note: *p < 0.01 as compared to control.
As it is seen, the number of metastases in the 
lungs of all treated mice did not differ versus control. 
At the same time, volume of the metastatic lesions 
in the DFMO and DFMO + nor-NOHA groups was near 
90% less versus control.
Taking in mind the importance of the ODC enzyme 
and PA synthesis for cell proliferation, the next sec-
tion of research was devoted to study of ODC activity 
in the cells of Lewis lung cancer after the action of in-
hibitors of PA metabolism. The experimental results 
are presented in Table 3.
 The data obtained show that ODC activity in the tumor 
increases during the tumor development. On 26th day 
of experiment, ODC activity in tumors in all treated groups 
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was decreased versus control (see Table 3). It may 
be expected that inhibition of ODC activity is the main 
cause of inhibition of tumor growth. Our preclinical data 
indicate that DFMO in combination with inhibitors of ar-
ginase has potential for chemoprevention of cancer and 
should be evaluated in other models and in combination 
with other drugs in anticipation of future clinical trials.
Table 3.  Effect of inhibitors of PA metabolism on ODC activity in cells 
of experimental Lewis lung carcinoma
Groups
Number 
of ani-
mals
13th day 26th day
ODC activity, 
A.U./mg pro-
tein
Inhi-
bition, 
%
ODC activity, 
A.U./mg protein
Inhi-
bition, 
%
Control 4 0.034 ± 0.002 − 0.578 ± 0.070 −
nor-NOHA 5 0.070 ± 0.012# 0 0.346 ± 0.046* 40
DFMO 4 0.010 ± 0.001# 0 0.355 ± 0.060** 39
DFMO + nor-
NOHA 3 0.019 ± 0.001
# 0 0.348 ± 0.050* 40
Note: #0.1 < p <0.25; *0.025 < p < 0.01; **0.01 < p < 0.005 as compared to control.
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